Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Yunnan Walvax Buys 58% Stake in Vaccine-Maker Zerun Biotech

publication date: Jan 14, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Yunnan Walvax Biotech paid $49.2 million to acquire a 58% stake in Shanghai Zerun Biotech, a fellow vaccine company. Walvax bought the stake by buying Wison (China) Investment’s equity in Zerun for $20.8 million, and then investing another $28.4 in Zerun directly. For Walvax, the deal improves its R&D capability in recombinant vaccines, and it adds to the pipeline one marketed vaccine and seven others in various stages of development. More details....

Stock Symbol: (SHE: 300142)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors